Bridgeway Capital Management’s C4 Therapeutics CCCC Stock Holding History

Bridgeway Capital Management’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$612K	Hold	131,100	–	–	0.01%	810
2026 Q1	$345K	Hold	131,100	–	–	0.01%	900
2025 Q4	$250K	Buy	131,100 +51,200	+64%	+$121K	0.01%	976
2025 Q3	$177K	Sell	79,900 -25,000	-24%	-$60K	﹤0.01%	1035
2025 Q2	$150K	Sell	104,900 -25,000	-19%	-$36.4K	﹤0.01%	1015
2025 Q1	$208K	Buy	+129,900	New	+$387K	0.01%	920
2024 Q3	–	Sell	-49,000	Closed	-$226K	–	1268
2024 Q2	$226K	Hold	49,000	–	–	0.01%	1030
2024 Q1	$400K	Sell	49,000 -75,000	-60%	-$581K	0.01%	980
2023 Q4	$701K	Sell	124,000 -25,000	-17%	-$57K	0.02%	851
2023 Q3	$277K	Buy	149,000 +49,000	+49%	+$149K	0.01%	1028
2023 Q2	$275K	Buy	+100,000	New	+$321K	0.01%	1064

Other funds holding CCCC

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bridgeway Capital Management's CCCC Position: Q2 2026 in Review

Bridgeway Capital Management held its C4 Therapeutics (CCCC) position steady in Q2 2026 at 131,100 shares worth $612K. The position accounts for 0.01% of the portfolio, ranked #810.

Bridgeway Capital Management first reported a position in CCCC in Q2 2023 and has held it in 11 quarters since. The position peaked at $701K in Q4 2023. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

Bridgeway Capital Management held 131,100 shares of C4 Therapeutics worth $612K as of Q2 2026.
Bridgeway Capital Management left its C4 Therapeutics share count unchanged in Q2 2026.
C4 Therapeutics made up 0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #810 holding.
Bridgeway Capital Management first reported a position in C4 Therapeutics in Q2 2023 and has held it in 11 quarters since.
Bridgeway Capital Management's C4 Therapeutics position peaked at $701K in Q4 2023.
148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.